C
Crescendo Bioscience
Nable more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients
About Crescendo Bioscience
Crescendo Bioscience, a subsidiary of Myriad Genetics, specializes in molecular diagnostics with a focus on identifying hereditary cancer risks and optimizing treatment plans through genetic insights. The company serves healthcare providers and patients, primarily in the oncology and pharmacogenomics sectors. Operating within the precision medicine market, Crescendo Bioscience leverages advanced sequencing and analysis techniques to offer multi-gene panel tests, such as the Myriad myRisk Hereditary Cancer test, which assesses the risk for eight different hereditary cancers. Their GeneSight test is another key product, providing pharmacogenomic insights to help healthcare providers tailor antidepressant treatments for better patient outcomes. The business model revolves around selling these diagnostic tests to healthcare providers, who then use the results to inform patient care. Revenue is generated through test sales and associated services. Crescendo Bioscience's commitment to innovation and patient care drives its operations, aiming to answer the most pressing questions about disease and improve patient outcomes. Keywords: molecular diagnostics, hereditary cancer, genetic insights, precision medicine, oncology, pharmacogenomics, sequencing, multi-gene panel, patient outcomes, healthcare providers.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- San Francisco, United States
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 73.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, DNA, Genetics and genomics, Molecular, Spinout, Genome Engineering, Biotech and Pharma, medical testing, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Crescendo Bioscience.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Feb 2014 | $270M | $270M | Myriad Genetics | — |
| SERIES DOther financing | Jan 2013 | $28M | $112M | Safeguard Scientifics · Kleiner Perkins · Calibrium · Mohr Davidow Ventures | — |
Growth signals
Latest recorded traffic for Crescendo Bioscience is 120 monthly website visits, down 66.7% over the last three months. Crescendo Bioscience's team grew 17.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Mohr Davidow Ventures
Kleiner Perkins
Series B and later3 investors entered at this stage
Calibrium
Safeguard Scientifics
Skyline Ventures
Other known investors2 additional known investors
Myriad Genetics
Oklahoma Medical Research Foundation
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Crescendo Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Crescendo Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.